Conducting a COVID-19 Vaccine Trial Using CTSA Resources: Lessons Learned

AZD1222 is being developed for the prevention of COVID-19. AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein, commonly known as the “Oxford vaccine” or as “ChAdOx.” We describe a “scale up” approach utilizing CTSA resources to conduct a multisite clinical trial testing a COVID vaccine in the midst of a pandemic incorporating at risk populations.